Asset Details
Do you wish to reserve the book?
3383 Validation and optimisation of a commercial cell-based assay for detection of nodo-paranodal antibodies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
3383 Validation and optimisation of a commercial cell-based assay for detection of nodo-paranodal antibodies
Do you wish to request the book?
3383 Validation and optimisation of a commercial cell-based assay for detection of nodo-paranodal antibodies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
3383 Validation and optimisation of a commercial cell-based assay for detection of nodo-paranodal antibodies
2025
Overview
Background/ObjectivesA minority of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have autoantibodies against components of nodal and paranodal structures in peripheral nerves. These autoantibodies are associated with lower likelihood of response to intravenous immunoglobulin (IVIg) treatment and increased responsiveness to B cell depletion. An easily available, reliable diagnostic assay for the detection of nodo-paranodal antibodies is a major unmet need.MethodsWe tested serum samples from patients with CIDP and healthy controls for the presence of antibodies against neurofascin 155 (NF155), neurofascin 186 (NF186), contactin-1 (CNTN1) and the contactin1/contactin-associated protein 1 (CNTN1/CASPR1) complex using a commercial transfected HEK-293 cell-based indirect immunofluorescence immunoassay (EUROImmun). We modified the manufacturer’s staining protocol using an additional incubation step to increase analytical sensitivity of the assay.ResultsWe detected nodo-paranodal antibodies in four out of 22 CIDP patients, including three who had previously tested positive for nodo-paranodal antibodies using enzyme-linked immunosorbent assay (ELISA), with no positive tests in 52 healthy controls. The modified staining protocol successfully increased the analytical sensitivity of the assay. Our modified assay demonstrated robustness in the presence of common interfering substances and serum with high nonspecific background immunofluorescent staining.ConclusionWe successfully modified and validated a commercial indirect immunofluorescence immunoassay for the qualitative detection of antibodies against NF155, CNTN1 and CNTN1/CASPR1. This could lead to more rapid diagnosis of patients with these autoantibodies, avoiding costly and ineffective treatments. Evaluation of the assay in a larger CIDP cohort and disease control group is ongoing. Testing is now available in Australia.
Publisher
BMJ Publishing Group LTD
Subject
